

Effect of Platinum(II) Complexes of Benzoic and 3-Methoxybenzoic Acid Hydrazides on *Saccharomyces cerevisiae*

Svoboda Tabakova and Nicolay Dodoff

Institute of Molecular Biology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Block 21, 1113 Sofia, Bulgaria

Z. Naturforsch. **50c**, 732–734 (1995);
received July 29, 1994/June 29, 1995

Pt(II) Complexes, Hydrazides, Yeast Susceptibility

The inhibitory effect of benzoic acid hydrazide (bah) and 3-methoxybenzoic acid hydrazide (mbah) on *Saccharomyces cerevisiae* strains has been compared to that of their platinum(II) complexes: *cis*-[Pt(bah)₂X₂], *cis*-[Pt(NH₃)(bah)Cl₂]·0.5 H₂O, *cis*-[Pt(mbah)₂X₂] and *cis*-[Pt(NH₃)(mbah)Cl₂] (X = Cl, Br = I), and *cis*-[Pt(NH₃)₂Cl₂]. The minimal inhibitory concentrations for bah and mbah were 5000–20,000 μM whereas for their Pt(II) complexes they were much less (25–800 μM) and did not exceed those of cisplatin (100–800 μM). The activity of the Pt(II) complexes of bah and mbah varied in wide ranges for the different yeast strains tested. Osmotically unstable mutants were found to be more susceptible. The most active complexes were [Pt(NH₃)(bah)Cl₂]·0.5 H₂O and [Pt(NH₃)(mbah)Cl₂].

In the search for more efficient analogues of the anticancer agent *cis*-diamminedichloroplatinum (*cis*-platin), special attention has been paid to the use of biologically active compounds as ligands (Hydes and Russel, 1988). Recently Dodoff *et al.* (1994) described the synthesis, characterization and cytotoxic effect of a series of new platinum(II) complexes of benzoic acid hydrazide (bah) and 3-methoxybenzoic acid hydrazide (mbah): *cis*-[Pt(bah)₂X₂], *cis*-[Pt(NH₃)(bah)Cl₂]·0.5 H₂O, *cis*-[Pt(mbah)₂X₂] and *cis*-[Pt(NH₃)(mbah)Cl₂] (X = Cl, Br, I). The interest in platinum complexes of such ligands was provoked by the literature data about diverse biological activity of carboxylic acid hydrazides and of some of their transition metal complexes: antitumor (Rutner *et al.*, 1974; Tret'yakov *et al.*, 1983; Tret'yakov *et al.*, 1989), mutagenic (Riggin and Schultz, 1986), antimicrobial (Kar *et al.*, 1980; Kutsenko *et al.*, 1980) and antifungal

(Zsolnai, 1962; Narang and Singh, 1985; Narang *et al.*, 1990).

In the present study we compare the antiyeast activity of bah and mbah to that of their platinum(II) complexes and cisplatin. We have included in the assay *Saccharomyces cerevisiae* mutants with defective cell wall and their parental strains to find out whether their susceptibility to the test compounds would be different.

The values of the minimal inhibitory concentration (MIC) and the 50%-inhibitory concentration (IC₅₀) of the compounds are presented in Table I. The MIC values of bah and mbah were 5000–20,000 μM, while for their Pt(II) complexes they were more than 50-fold lower (25–800 μM).

The activity of bah was equal to that of mbah against each strain and no difference in susceptibility of the strains, except VY1160, was observed. The activity of Pt(II) complexes of these ligands, however, varied largely among the strains tested.

The most active were the ammonia-containing complexes, [Pt(NH₃)(bah)Cl₂]·0.5 H₂O and [Pt(NH₃)(bah)Cl₂] (MICs ranging from 25 to 200 μM), and the least active were cisplatin [Pt(bah)₂I₂] and [Pt(mbah)₂I₂]. No significant differences were observed in the MIC values of [Pt(bah)₂Cl₂], [Pt(bah)₂Br₂], [Pt(mbah)₂Cl₂] and [Pt(mbah)₂Br₂], but it should be noted that against the strain VY1160, the IC₅₀ values of the later two complexes were about 10-fold lower than for the first two.

Although the MIC values of the Pt(II) complexes of bah and mbah were generally lower, they were similar to those of cisplatin, and at the same time they were much lower as compared to the free ligands. This suggests that the new complexes act by a mechanism, common to that of cisplatin, *i.e.* by binding mainly to DNA (Lippert, 1992). Osmotically unstable mutants were observed to be more susceptible to the complexes tested than their respective parental strains. An explanation may be sought in the interaction of the complexes with the altered cell wall and increased availability in the cell, but a supposition that the cell surface may be the site of action of metal complexes (Bunker and James, 1989) is unlikely to apply to platinum complexes. Recently, a protein conferring *cis*-

Reprint requests to Dr. S. Tabakova.

0939–5075/95/0900–0732 \$ 06.00 © 1995 Verlag der Zeitschrift für Naturforschung. All rights reserved.

N



Dieses Werk wurde im Jahr 2013 vom Verlag Zeitschrift für Naturforschung in Zusammenarbeit mit der Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. digitalisiert und unter folgender Lizenz veröffentlicht: Creative Commons Namensnennung-Keine Bearbeitung 3.0 Deutschland Lizenz.

Zum 01.01.2015 ist eine Anpassung der Lizenzbedingungen (Entfall der Creative Commons Lizenzbedingung „Keine Bearbeitung“) beabsichtigt, um eine Nachnutzung auch im Rahmen zukünftiger wissenschaftlicher Nutzungsformen zu ermöglichen.

This work has been digitalized and published in 2013 by Verlag Zeitschrift für Naturforschung in cooperation with the Max Planck Society for the Advancement of Science under a Creative Commons Attribution-NoDerivs 3.0 Germany License.

On 01.01.2015 it is planned to change the License Conditions (the removal of the Creative Commons License condition “no derivative works”). This is to allow reuse in the area of future scientific usage.

Table I. Inhibitory effect of benzoic acid hydrazides (bah) and methoxybenzoic acid hydrazides (mbah) and their Pt(II) complexes on the growth of *Saccharomyces cerevisiae*, expressed through MIC and IC₅₀ in μM .

Compound	Strain	A 364		SY 15 ^c		E 1278		VY 481 ^c		S 288 ^c		VY 1160 ^c	
		MIC	IC ₅₀	MIC	IC ₅₀	MIC	IC ₅₀	MIC	IC ₅₀	MIC	IC ₅₀	MIC	IC ₅₀
bah ^a		20,000	—	20,000	—	20,000	—	20,000	—	20,000	—	5000	—
[Pt(bah) ₂ Cl ₂]		200	60	50	30	200	70	20	13	100	50	100	40
[Pt(NH ₃)(bah)Cl] ₂ · 0.5 H ₂ O		200	90	50	30	100	40	20	10	100	60	50	4
[Pt(bah) ₂ Br ₂]		200	40	100	70	200	70	50	30	100	40	100	50
[Pt(bah) ₂ I ₂]		400	80	200	100	800	120	400	70	400	70	200	30
mbah ^b		20,000	—	20,000	—	20,000	—	20,000	—	20,000	—	5000	—
[Pt(mbah) ₂ Cl ₂]		200	20	100	60	200	80	20	6	100	30	50	6
[Pt(NH ₃)(mbah)Cl] ₂		200	60	50	30	200	80	20	10	100	80	50	5
[Pt(mbah) ₂ Br ₂]		200	40	50	30	200	50	20	10	100	30	50	5
[Pt(mbah) ₂ I ₂]		400	60	200	150	800	200	400	150	400	150	200	20
cis-[Pt(NH ₃) ₂ Cl ₂]		800	120	100	80	800	100	800	70	400	200	200	10

^a Benzoic acid hydrazides.^b Methoxybenzoic acid hydrazides.^c Osmotically unstable mutants of *Saccharomyces cerevisiae*.

platin susceptibility has been isolated from yeast (Brown *et al.*, 1993). Assuming that the Pt(II) complexes of bah and mbah act by a similar mechanism as cisplatin it may be speculated that different susceptibility of the strain is associated with the concentration of the structure specific recognition proteins in the cell.

No correlation was found between the activities of the complexes against yeasts and against Friend leukemia cells, although the IC₅₀ values for YV 1160 strain were similar to those obtained for Friend leukemia cells, as reported by Dodoff *et al.* (1994).

In conclusion it may be said that participation in Pt(II) complexes dramatically increases the antiyeast activity of bah and mbah and is probably associated with a different mechanism of action. Susceptibility of yeasts to Pt(II) complexes varies widely among the strains. Osmotically unstable mutants are more sensitive than their parental strains.

Experimental

The ligands bah and mbah and cis-[Pt(NH₃)₂Cl₂] were prepared according to Struve (1894), Hutton (1955) and Spassovska *et al.* (1981),

respectively. The platinum complexes of bah and mbah were synthesized as described by Dodoff *et al.* (1994).

Yeast susceptibility was studied by the minimal inhibitory concentrations (MIC) and the IC₅₀ values. DMSO solutions (8–16,000 μM) of the compounds were added to Sabouraud nutrient medium complemented with 10% sorbitol, the DMSO/broth ratio being 1:10. MICs were determined by the twofold broth dilution method (Reiner, 1982), the final inoculum size being 1×10^5 cfu/ml. Readings were made after 48 h of incubation at 30 °C.

IC₅₀ were extrapolated from the growth inhibition (I, %) vs. concentration curve (Galgiani *et al.*, 1976). I, % was calculated as $(A_c - A_i) : A_c \times 100$, A_c being the optical density at 520 nm of cultures, free from an inhibitor and A_i the respective optical densities of cultures grown in the presence of 800 through 80 and 8 μM of a test compound at the 12th and 16th hour.

Acknowledgements

The authors thank Prof. Dr. P. Venkov from the Institute of Molecular Biology, Sofia, for supplying the *Saccharomyces cerevisiae* strains from his collection.

- Brown S., Kellet P. J. and Lippert S. J. (1993), Yeast protein that binds to platinated DNA and confers sensitivity to *cis*-platin. *Science* **261**, 603–605.
- Bunker J. C. and James A. M. (1989), Microcalorimetric studies of the effect of platinum group metal complexes on bacterial growth. *Microbios* **58**, 83–93.
- Dodoff N., Grancharov K., Gugova R. and Spassovska N. (1994), Platinum(II) complexes of benzoic and methoxybenzoic acid hydrazides. Synthesis, characterization and cytotoxic effect. *J. Inorg. Biochem.* **54**, 221–233.
- Galgiani J. N. and Stevens D. A. (1976), Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. *Antimicrobial Agents and Chemotherapy* **10**, 721–726.
- Hutton K. (1955), The synthesis of some new phenylurethans as potential local anesthetics. *J. Org. Chem.* **20**, 855–859.
- Hydes P. C. and Russel M. J. H. (1988), Advances in platinum chemotherapy. *Cancer Metastasis Rev.* **7**, 67–89.
- Kar A., Guignani H. C. and Madumere U. A. (1980), Synthesis and antimicrobial activity of some antranilic acid derivatives. *Pharmazie* **35**, 466–468.
- Kutsenko T. A., Shamrai A. E., Rudenko A. V., Movchan A. S. and Shevchenko L. J. (1980), Study of the antimicrobial action of some ambem derivatives. *Fiziol. Akt. Veshchestva* **12**, 86–87.
- Lippert B. (1992), From cisplatin to artificial nucleates. The role of metal ion–nucleic acid interactions in biology. *Biomaterials* **5**, 195–208.
- Narang K. K. and Singh M. (1985), Complexes of Zn(II), Cu(II), Ni(II) and Co(II) tetrathiocyanatomercurates(II) with hydrazides and their biological activity. *Synth. React. Inorg. Met.-Org. Chem.* **15**, 821–837.
- Narang K. K., Pandey J. P., Singh K. P. and Rai P. K. (1990), Synthesis, characterization, IR and electronic spectra, magnetic moments and biological activity of trinuclear nickel(II) tetrathiocyanatobisargentate(I) complexes with hydrazides and hydrazones. *Synth. React. Inorg. Met.-Org. Chem.* **20**, 1301–1316.
- Reiner R. (1982), *Antibiotics, an Introduction*. Thieme-Stratton Verlag, Stuttgart, New York, pp. 21–23.
- Riggin G. W. and Schultz T. W. (1986), Teratogenic effects of benzoyl hydrazine on frog embryo. *Trans. Am. Microsc. Soc.* **105**, 197–210.
- Rutner H., Lewin N., Woodbury E. C., McBride T. J. and Rao K. V. (1974), Antitumor activity of some acyl hydrazines. *Cancer Chemother. Rep., Part 1*, **58**, 803–810.
- Spassovska N. C., Bontchev P. R., Grancharov K. C., Golovinsky E. V. (1981), Method for preparation of *cis*-diamminedichloroplatinum. Bulgarian Patent Reg. No. 54667.
- Struve A. (1894), Über Benzhydrazid. *J. Prakt. Chem.* **50**, 295–301.
- Tret'yakov A. V., Ratovitskii E. A., Petrov A. S. and Golovatova W. A. (1983), Effect of antiestrogens and antiandrogens from a class of acyl hydrazines on nucleoside triphosphatase properties and adenyl nucleotide content in normal and cancer cell nuclei. *Vopr. Med. Khim.* **29**, 98–102.
- Tret'yakov A. V., Onishchuk F. D. and Filov V. A. (1989), Toxicity of *p*-aminobenzhydrazide and its effect on biosynthesis of nucleic acids in cultures of intact and tumor cells. *Byull. Eksp. Biol. Med.* **107**, 200–201.
- Zsolnai T. (1962), New fungistatic compounds. IV. Hydrazine derivatives and organic bases or their salts. *Biochem. Pharmacol.* **11**, 995–1016.